Katherine C Konvinse1, Jason A Trubiano2, Rebecca Pavlos3, Ian James4, Christian M Shaffer5, Cosmin A Bejan6, Ryan J Schutte7, David A Ostrov7, Mark A Pilkinton8, Misha Rosenbach9, Jeffrey P Zwerner10, Kristina B Williams8, Jack Bourke11, Patricia Martinez12, Francois Rwandamuriye4, Abha Chopra4, Mark Watson4, Alec J Redwood4, Katie D White8, Simon A Mallal13, Elizabeth J Phillips14. 1. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tenn. 2. Department of Infectious Diseases, Austin Health, Heidelberg, Australia; National Centre for Infections in Cancer, Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Australia; Department of Medicine, University of Melbourne, Parkville, Australia. 3. Telethon Kids Institute, University of Western Australia, Nedlands, Australia. 4. Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia. 5. Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. 6. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tenn. 7. Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Fla. 8. Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. 9. Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pa. 10. Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tenn. 11. Department of Clinical Immunology, Fiona Stanley Hospital, Murdoch, Australia. 12. Department of Clinical Immunology, Fiona Stanley Hospital, Murdoch, Australia; Department of Clinical Immunology, Royal Perth Hospital, Perth, Australia; Division of Pathology and Laboratory Medicine, School of Medicine, Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia, Crawley, Australia. 13. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tenn; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn. 14. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tenn; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tenn. Electronic address: elizabeth.j.phillips@vumc.org.
Abstract
BACKGROUND: Vancomycin is a prevalent cause of the severe hypersensitivity syndrome drug reaction with eosinophilia and systemic symptoms (DRESS), which leads to significant morbidity and mortality and commonly occurs in the setting of combination antibiotic therapy, affecting future treatment choices. Variations in HLA class I in particular have been associated with serious T cell-mediated adverse drug reactions, which has led to preventive screening strategies for some drugs. OBJECTIVE: We sought to determine whether variation in the HLA region is associated with vancomycin-induced DRESS. METHODS: Probable vancomycin-induced DRESS cases were matched 1:2 with tolerant control subjects based on sex, race, and age by using BioVU, Vanderbilt's deidentified electronic health record database. Associations between DRESS and carriage of HLA class I and II alleles were assessed by means of conditional logistic regression. An extended sample set from BioVU was used to conduct a time-to-event analysis of those exposed to vancomycin with and without the identified HLA risk allele. RESULTS: Twenty-three subjects met the inclusion criteria for vancomycin-associated DRESS. Nineteen (82.6%) of 23 cases carried HLA-A*32:01 compared with 0 (0%) of 46 of the matched vancomycin-tolerant control subjects (P = 1 × 10-8) and 6.3% of the BioVU population (n = 54,249, P = 2 × 10-16). Time-to-event analysis of DRESS development during vancomycin treatment among the HLA-A*32:01-positive group indicated that 19.2% had DRESS and did so within 4 weeks. CONCLUSIONS: HLA-A*32:01 is strongly associated with vancomycin-induced DRESS in a population of predominantly European ancestry. HLA-A*32:01 testing could improve antibiotic safety, help implicate vancomycin as the causal drug, and preserve future treatment options with coadministered antibiotics.
BACKGROUND:Vancomycin is a prevalent cause of the severe hypersensitivity syndrome drug reaction with eosinophilia and systemic symptoms (DRESS), which leads to significant morbidity and mortality and commonly occurs in the setting of combination antibiotic therapy, affecting future treatment choices. Variations in HLA class I in particular have been associated with serious T cell-mediated adverse drug reactions, which has led to preventive screening strategies for some drugs. OBJECTIVE: We sought to determine whether variation in the HLA region is associated with vancomycin-induced DRESS. METHODS: Probable vancomycin-induced DRESS cases were matched 1:2 with tolerant control subjects based on sex, race, and age by using BioVU, Vanderbilt's deidentified electronic health record database. Associations between DRESS and carriage of HLA class I and II alleles were assessed by means of conditional logistic regression. An extended sample set from BioVU was used to conduct a time-to-event analysis of those exposed to vancomycin with and without the identified HLA risk allele. RESULTS: Twenty-three subjects met the inclusion criteria for vancomycin-associated DRESS. Nineteen (82.6%) of 23 cases carried HLA-A*32:01 compared with 0 (0%) of 46 of the matched vancomycin-tolerant control subjects (P = 1 × 10-8) and 6.3% of the BioVU population (n = 54,249, P = 2 × 10-16). Time-to-event analysis of DRESS development during vancomycin treatment among the HLA-A*32:01-positive group indicated that 19.2% had DRESS and did so within 4 weeks. CONCLUSIONS:HLA-A*32:01 is strongly associated with vancomycin-induced DRESS in a population of predominantly European ancestry. HLA-A*32:01 testing could improve antibiotic safety, help implicate vancomycin as the causal drug, and preserve future treatment options with coadministered antibiotics.
Keywords:
T-cell hypersensitivity; Vancomycin; antibiotic allergy; delayed hypersensitivity; drug reaction with eosinophilia and systemic symptoms; human leukocyte antigen
Authors: S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen Journal: Lancet Date: 2002-03-02 Impact factor: 79.321
Authors: Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses Journal: Lancet Date: 2002-03-30 Impact factor: 79.321
Authors: Annalise M Martin; David Nolan; Silvana Gaudieri; Coral Ann Almeida; Richard Nolan; Ian James; Filipa Carvalho; Elizabeth Phillips; Frank T Christiansen; Anthony W Purcell; James McCluskey; Simon Mallal Journal: Proc Natl Acad Sci U S A Date: 2004-03-15 Impact factor: 11.205
Authors: Simon Mallal; Elizabeth Phillips; Giampiero Carosi; Jean-Michel Molina; Cassy Workman; Janez Tomazic; Eva Jägel-Guedes; Sorin Rugina; Oleg Kozyrev; Juan Flores Cid; Phillip Hay; David Nolan; Sara Hughes; Arlene Hughes; Susanna Ryan; Nicholas Fitch; Daren Thorborn; Alastair Benbow Journal: N Engl J Med Date: 2008-02-07 Impact factor: 91.245
Authors: Francois X Rwandamuriye; Abha Chopra; Katherine C Konvinse; Linda Choo; Jason A Trubiano; Christian M Shaffer; Mark Watson; Simon A Mallal; Elizabeth J Phillips Journal: J Mol Diagn Date: 2019-05-31 Impact factor: 5.568
Authors: Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips Journal: Br J Clin Pharmacol Date: 2019-11-05 Impact factor: 4.335
Authors: Wan-Chun Chang; Riichiro Abe; Paul Anderson; Wanpen Anderson; Michael R Ardern-Jones; Thomas M Beachkofsky; Teresa Bellón; Agnieszka K Biala; Charles Bouchard; Gianpiero L Cavalleri; Nicole Chapman; James Chodosh; Hyon K Choi; Ricardo R Cibotti; Sherrie J Divito; Karen Dewar; Ulrike Dehaeck; Mahyar Etminan; Diane Forbes; Esther Fuchs; Jennifer L Goldman; James H Holmes; Elyse A Hope; Shuen-Iu Hung; Chia-Ling Hsieh; Alfonso Iovieno; Julienne Jagdeo; Mee Kum Kim; David M Koelle; Mario E Lacouture; Sophie Le Pallec; Rannakoe J Lehloenya; Robyn Lim; Angie Lowe; Jean McCawley; Julie McCawley; Robert G Micheletti; Maja Mockenhaupt; Katie Niemeyer; Michael A Norcross; Douglas Oboh; Cristina Olteanu; Helena B Pasieka; Jonathan Peter; Munir Pirmohamed; Michael Rieder; Hajirah N Saeed; Neil H Shear; Christine Shieh; Sabine Straus; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Sheng-Ying Tsou; Mayumi Ueta; Simona Volpi; Chen Wan; Hongsheng Wang; Zhao-Qing Wang; Jessica Weintraub; Cindy Whale; Lisa M Wheatley; Sonia Whyte-Croasdaile; Kristina B Williams; Galen Wright; Sonia N Yeung; Li Zhou; Wen-Hung Chung; Elizabeth J Phillips; Bruce C Carleton Journal: J Dermatol Sci Date: 2020-03-07 Impact factor: 4.563
Authors: Leena Choi; Cole Beck; Elizabeth McNeer; Hannah L Weeks; Michael L Williams; Nathan T James; Xinnan Niu; Bassel W Abou-Khalil; Kelly A Birdwell; Dan M Roden; C Michael Stein; Cosmin A Bejan; Joshua C Denny; Sara L Van Driest Journal: Clin Pharmacol Ther Date: 2020-02-11 Impact factor: 6.875
Authors: Pooja Deshpande; Rebecca J Hertzman; Amy M Palubinsky; Jason B Giles; Jason H Karnes; Andrew Gibson; Elizabeth J Phillips Journal: Clin Pharmacol Ther Date: 2021-07-17 Impact factor: 6.875
Authors: Santiago Alvarez-Arango; Sharmitha Yerneni; Olive Tang; Li Zhou; Christian M Mancini; Suzanne V Blackley; Corinne Allison Keet; Kimberly G Blumenthal Journal: J Allergy Clin Immunol Pract Date: 2020-10-01